Jaguar Health (FRA:1JA1) Short Interest


FRA:1JA1 Jaguar Health Inc FRA:1JA1
22 GF Score
Price €0.00
! 3 Warning Signs
View Full Analysis

What is Jaguar Health Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:1JA1 vs BBLG, VBIO, PKTX: Short Interest Comparison

For the Biotechnology subindustry, Jaguar Health's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jaguar Health Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's Short Interest distribution charts can be found below:

* The bar in red indicates where Jaguar Health's Short Interest falls into.


FRA:1JA1
22GF Score
Jaguar Health Inc FRA:1JA1
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jaguar Health Business Description

Other Exchanges JAGX:USA
Address 200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
22GF Score

Get the complete analysis for FRA:1JA1

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price